Major slash in prices on cancer and diabetic drugs: Pricing Regulatory Authority

By  ,  Onlymyhealth editorial team
Mar 08, 2017


National Pharmaceutical Pricing Authority (NPPA) in a statement said cancer and diabetic drugs have seen a major price slash over the years, particularly in the recent past, in the country. Now these drugs are expected to within the reach of a wide population base.


The drug pricing regulator, in a tweet on Monday last, said there has been "significant price reduction" since March 2016. Over the cancer drugs the reduction amounts up to 86 per cent and the reduction up to 42 per cent in major diabetic treating drugs.


The price of Iressa of Astrazeneca Pharma India, one of the major cancer drugs, has been reduced by a whopping Rs 3,977. That constitutes to 86 per cent on the original price Rs 29,259.
The price reduction also covers other important cancer drugs as well. Nanoxel (Rs 1,035) and Frastim (Rs 1,273) have been slashed by 55 per cent and 51 per cent respectively.


The same has been the case with diabetic drugs too. Sun Pharmaceuticals’ Glypride has been priced at Rs 53 – a reduction of about 42 per cent from Rs 91.


The NPPA also said that the price cut also covers the drugs from other pharma firms including Dr Reddy's Lab, Abbot Healthcare, Micro Labs, Dabur India, Lupin and quite a few others.

 

Image source: Shutterstock

Source: IANS

Read More Heath News

Loading...
Is it Helpful Article?YES548 Views 0 Comment
I have read the Privacy Policy and the Terms and Conditions. I provide my consent for my data to be processed for the purposes as described and receive communications for service related information.
This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK